Consumer products containing cannabis-derived CBN to be banned from June

A revised ordinance will ban consumer products containing cannabis-derived CBN starting in June. Only patients with specific conditions, such as intractable diseases without alternative treatments, will be allowed to use them.

The Japan Times reports that under a revised ordinance from the Ministry of Health, Labour and Welfare (MHLW), consumer products containing CBN—a substance derived from cannabis—will be banned starting in June. Access will be restricted to patients with specific conditions, such as intractable diseases with no alternative treatment options. The article, published on March 19, 2026, lists keywords including drugs, MHLW, CBN, and marijuana. This policy targets consumer products while preserving limited medical applications.

Articoli correlati

Illustration of Anvisa approving medical cannabis cultivation in Brazil, featuring scientists in a lab with plants and official documents.
Immagine generata dall'IA

Anvisa approva la coltivazione di cannabis per scopi medici

Riportato dall'IA Immagine generata dall'IA

L'Agenzia Nazionale di Vigilanza Sanitaria (Anvisa) ha approvato, il 28 gennaio 2026, risoluzioni che consentono la coltivazione di cannabis per trattamenti sanitari e ricerca, insieme a nuove vie di somministrazione e importazioni di piante. Questo passo segna un progresso nella catena produttiva nazionale, facilitando l'accesso ai farmaci derivati da piante. Le modifiche ampliano le opzioni per pazienti con malattie gravi mantenendo restrizioni rigorose.

A comprehensive analysis of over 2,500 studies shows that medical cannabis has strong evidence for only a few specific uses, despite widespread public belief in its broader effectiveness. Led by UCLA Health researchers, the review highlights gaps between perceptions and scientific proof for conditions like chronic pain and anxiety. It also identifies potential risks, particularly for adolescents and daily users.

Riportato dall'IA

A comprehensive review of clinical trials suggests that cannabis products high in THC may provide modest, short-term relief for chronic pain, especially neuropathic types, but with notable side effects. In contrast, CBD-dominant products offer no clear advantages. Researchers call for more long-term studies to assess safety and efficacy.

The U.S. Supreme Court heard arguments in United States v. Hemani, challenging a federal law that prohibits unlawful drug users from possessing firearms. Justices from both conservative and liberal sides expressed skepticism about the statute's broad application, particularly to marijuana users. The case stems from a 2022 incident involving Ali Danial Hemani, who was convicted after admitting to frequent marijuana use.

Riportato dall'IA Verificato

A statewide analysis led by the University of Colorado Boulder found that about 43% of cannabis flower products sold in Colorado listed THC levels outside the state’s ±15% accuracy threshold—most overstating potency—while 96% of concentrates matched their labels. The results point to a need for tighter testing and clearer packaging to bolster consumer trust.

Prime Minister Kim Min-seok said on Thursday, January 15, 2026, that the government will implement thorough measures to bolster safety rules on chemical goods, citing the long-running consumer goods disaster over toxic humidifier disinfectant. He emphasized that ensuring the safety and health of the people is the government's top policy priority.

Riportato dall'IA

Scientists at the Weizmann Institute of Science in Israel have modified tobacco plants to produce five powerful psychedelic compounds typically found in mushrooms, plants, and toads. The technique uses temporary genetic changes to create a sustainable source for research and potential medicines. Experts say this could simplify production compared to chemical synthesis or harvesting from nature.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta